What Was Presented

Teva Pharmaceuticals presented UZEDY data at Psych Congress in New Orleans, LA, September 15 – 19, 2026.

UZEDY, a risperidone product, is indicated for treatment in adults with schizophrenia and for maintenance treatment in bipolar I disorder.

Highlights

  • UZEDY is indicated for treatment in adults with schizophrenia and for maintenance treatment in bipolar I disorder.
  • The data put PP1m cost at 5724.8 and UZEDY cost at 4688.1, with savings per patient of 1036.7.
  • Treatment failure in BD-I was reported at 47 for UZEDY and 63 for the other treatment comparator.

What The Reported Numbers Say

The single-source cost data put PP1m at 5724.8 and UZEDY at 4688.1, with savings per patient of 1036.7.

In BD-I, treatment failure was reported at 47 for UZEDY and 63 for the other treatment comparator.

The adherence comparison versus risperidone microspheres showed adherence odds of 3.6 and discontinuation odds of 0.2 for UZEDY.

Care-Use Measures To Note

UZEDY was reported to reduce emergency department visits versus risperidone microspheres.

Against PP1m, the reported emergency department visit rate was 27.8 for PP1m and 22 for UZEDY.